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The Colon Cancer Awareness Month is an annual 
celebration that is observed during the month of 
March, to increase awareness of colon cancer.  
 
Colorectal Cancer (CRC) is a malignant tumour 
that arises from the inner wall of the large 
intestine (the colon). Being the 3rd most common 
cancer globally, CRC can gradually develop 
following an accumulation of different somatic or 
inherited changes within the genome and 
epigenome. These kind of transformations on 
pathological level can bring about the alteration of 
colonic mucosa into invasive cancer. The risk of 
CRC increases with increase in age, as well as in 
subjects who carry certain inherited genetic 
mutations, a personal or family history of 
colorectal neoplasia, or having inflammatory 
bowel disease (IBD). The challenge that the world 
is facing today is for the detection of even the most 
sensitive types of that which can be solved with 
the aid of biotechnology. In most of the cases, CRC 
is asymptomatic until its progression to advanced 
stages, the timely detection utilizing effective 
screening strategies, selection of relevant 
therapeutic approaches and efficient follow-up 
programs are absolutely necessary to turn down 
CRC associated mortalities. Biomarker 
recognition for CRC based on the individualized 
genotype and clinical information could simplify 
the classification of patients with certain types and 
stages of cancer to customize preventive and 
curative approaches. This editorial focuses on the 
various biotechnology techniques which can help 
in the early detection of CRC using antibody and 
antibody fragment. 
 
Myriad approaches in the detection of 
colorectal cancer 
CRC often seems to be a remediable and 
preventable disease due to its slow development 
unlike other solid malignancies. The stage of the 
tumour plays a crucial part at the time of diagnosis 
for patient survival. Therefore, timely detection of 
CRC through suitable screening strategies is a 
principle research goal that can lessen the 
incidence and mortality rates. As per the new 
findings in the molecular basis of CRC, extremely 
sensitive and specific molecular markers can be 
appropriate in early diagnosis of CRC and an 
alternate to conventional CRC screening 
practices.1 
 
The targeted therapies have got lesser side-effects 
in comparison with the routine standard 
chemotherapy and are under preclinical study or 
clinical trials. Targeted therapeutics depend on 
customized medicine and they remarkably extend 
the 5-year disease free survival.2 
 
The various facets through which diagnosis can 
get accelerated are the promising targeted 
therapeutic and drug delivery approaches in CRC 
including non-IG scaffold proteins, IG scaffold 
protein-based drugs, and aptamer.  
 
Antibody and antibody fragment in CRC 
targeted therapy 
For almost more than two decades, antibody-
based therapy has been of the utmost important 
immunotherapeutic approach for cancer target 
therapy. Worldwide, around 45 antibody-based 
products are being used currently against 
colorectal cancers with 63 billion US dollars in 
total sales for the year 2013.3 
 
Monoclonal antibody therapeutic effect occurs 
through different mechanisms such as blocking or 
inhibiting receptors for growth factors, 
suppressing tumor proliferation and apoptosis 
induction. Moreover, antibody-dependent cell 
mediated cytotoxicity or complement dependent 
cytotoxicity cause killing of tumor cells by 
recruitment of monocytes and macrophages. The 
vascular endothelial growth factor (VEGF) and the 
epidermal growth factor receptor (EGFR) 
signalling pathways are two important targets in 
colorectal cancers. Thus, they can be a point of 
focal interest during drug development and prime 
targets of antibody based treatment procedures.4,5 
 
The combination therapy consisting of 
monoclonal anti-body and chemotherapeutic 
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agents have shown a great anti-tumor effect and 
survival endpoints when compared to single agent 
therapy with a monoclonal antibody which shows 
only a little antitumor activity. A fusion form of 
Mabs along with toxins, radioisotopes or 
anticancer drugs for drug delivery against cancer 
cells has also been of interest to researchers. 
Furthermore, VEGF is a key pro-angiogenic factor 
that stimulates mitosis, angiogenesis and also 
controls the permeability of endothelial cells and 
inflammation. Currently, cetuximab, 
panitumumab, and bevacizumab are the three 
clinically-accessible Mabs that have been 
approved by Food and Drug Administration.4,5 
Bevacizumab monotherapy or in combination 
with fluoropyrimidines has been used in patients 
with metastatic CRC.  
 
Over the past few decades, genetic engineering 
has introduced a vast range of recombinant 
antibodies popularly known as bispecific 
antibodies. These next generation antibodies have 
the capability to recognize two epitopes on the 
same antigen.6 This type of antibody leads to 
increase in cell death in breast, colon, prostate, 
head-neck cancer cells. They also induce cell 
death in the carcinoma cells which are generally 
resistant to NK- mediated killing. In the last few 
years, targeting of different RNAses to cancer cells 
has also been a topic of remarkable interest. Given 
their enzymatic and non- mutagenic behavior, 
immunoribonucleases  (im-munoRNases)  have  
become  one  of  the  most upcoming therapeutic 
candidates. Moreover immunocytokine or 
diabody is an another potent approach to cancer 
therapy that targets various cytokine to cancerous 
cells. Recently, a diabody has been designed by 
combination of murine IL4 and the antibody 
fragment F8, extra-domain A of fibronectin as a 
marker for tumor-angiogenesis. As an 
immunocytokine with cytokine bioactivity and 
full antigen-binding activity, this structure leads 
to inhibition of tumor growth in the CT26 colon 
carcinoma.7 
 
Early detection through screening and assessment 
of genetic and environmental risk factors can 
improve the chances of survival. Further 
exploration into novel approaches, including the 
targeted agents, immune-therapeutics, and new 
chemotherapy combinations, is required to 
improve the prognosis and clinical outcomes for 
the patients suffering from colorectal cancer. 
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